176,738 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Premier Fund Managers Ltd

Premier Fund Managers Ltd acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, HoldingsChannel reports. The fund acquired 176,738 shares of the medical research company’s stock, valued at approximately $11,763,000.

Several other large investors have also modified their holdings of the business. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth about $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $39,000. Finally, Peoples Bank KS bought a new position in Edwards Lifesciences in the third quarter worth approximately $40,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.4 %

Edwards Lifesciences stock opened at $70.20 on Wednesday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market cap of $41.40 billion, a PE ratio of 10.13, a PEG ratio of 3.81 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business’s 50-day simple moving average is $67.59 and its two-hundred day simple moving average is $75.91.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company earned $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.27% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the subject of several research reports. Canaccord Genuity Group lowered their target price on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft cut their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Barclays reduced their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.